CONTRAFECT CORPORATION  Yonkers, NY, USA
contrafect.com

GRAM-NEGATIVE LYSINS
RECOMBINANT LYSIN PROTEIN

Direct-Acting Large Molecule Therapeutic
ContraFect has recently discovered 48 novel Gram-negative lysins. Lysins are bacteriophage-derived enzymes with potent antibacterial activity against antibiotic-resistant pathogens, robust anti-biofilm activity, a low propensity for resistance development, and pronounced synergy when used in combination with conventional antibiotics in pre-clinical studies. The CARB-X award will support development of a potential treatment for invasive infections caused by P. aeruginosa. These studies will allow ContraFect to proceed with further IND enabling work and the identification of lysins active against other Gram-negative pathogens. (NASDAQ:CFRX)

Current Development Stage: Hit to Lead

CARB-X Investment: Initial investment of up to $1.1m with potential option payments up to $1.0m.  Additional funds were awarded in 2019 for a total of $3.4m.

Initial CARB-X Investment Date: April 1, 2017